

Protalix BioTherapeutics, Inc.  
Form 8-K  
October 25, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): October 25, 2016**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**001-33357**

**65-0643773**



**Item 8.01. Other Events**

On October 25, 2016, Protalix BioTherapeutics, Inc. issued a press release announcing that the first patient has been dosed in its global phase III clinical trial of PRX-102 for the treatment of Fabry disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated October 25, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX  
BIOTHERAPEUTICS,  
INC.**

Date: October 25, 2016 By: /s/ Moshe Manor  
Moshe Manor  
Name: President and  
Title: Chief Executive  
Officer